Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china.
Jiujie CuiXiaochen ZhangShuli QuLiwei WangPublished in: Expert review of pharmacoeconomics & outcomes research (2020)
AG is likely a cost-effective option for the 1st-line mPC treatment compared with FOLFIRINOX in China from the perspective of healthcare system.